Search Results
Sep 09, 2026, 09:00 ET First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA
based on native GLP-1 and designed for once-weekly administration. It is being developed for the treatment of type 2 diabetes mellitus (T2DM) and for weight management in people with obesity or overweight. GZC8072 is underpinned by two proprietary technology platforms — NovaPeptide™,
More news about: Gan & Lee Pharmaceuticals
Sep 04, 2026, 06:47 ET Gan & Lee e Menarini Group collaborano per far progredire Bofanglutide in Europa
programma di somministrazione una volta ogni due settimane per la gestione del peso negli adulti affetti da obesità o sovrappeso, diabete mellito di tipo 2 (T2DM) e altre condizioni metaboliche. Il bofanglutide è un composto in fase di sperimentazione; la sua sicurezza ed efficacia non sono state stabilite o
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 04, 2026, 05:00 ET Cheetah Mobile To Report Second Quarter 2026 Financial Results on September 11, 2026
ID: 175-882-665Meeting Link: https://cmcm.meeting.tencent.com/dm/3QuXIZPgSezqDial-in Numbers:United States: +1 4153389272Mainland China: +86 (0)755 36550000Hong Kong: +852
More news about: Cheetah Mobile
Sep 03, 2026, 13:28 ET Gan & Lee y Menarini Group se asocian para impulsar el desarrollo de bofanglutida en Europa
desarrollo clínico con una pauta de administración quincenal para el control del peso en adultos con obesidad o sobrepeso, diabetes mellitus tipo 2 (DM2) y otras afecciones metabólicas. Bofanglutida es un compuesto en fase de investigación; su seguridad y eficacia no han sido establecidas ni autorizadas
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:08 ET Gan & Lee a Menarini Group uzavřely partnerství k prosazení přípravku bofanglutid v Evropě
klinickým vývojem s dávkovacím schématem jednou za dva týdny pro regulaci hmotnosti u dospělých trpících obezitou nebo nadváhou, diabetem mellitus 2. typu (T2DM) a dalšími metabolickými poruchami. Bofanglutid je látka ve fázi klinického výzkumu; jeho bezpečnost a účinnost nebyly dosud potvrzeny ani schváleny
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:04 ET Gan & Lee und die Menarini Group schließen Partnerschaft zur Weiterentwicklung von Bofanglutide in Europa
Rahmen eines zweiwöchentlichen Dosierungsschemas (q2w) zur Gewichtsregulierung bei Erwachsenen mit Adipositas oder Übergewicht, Typ-2-Diabetes mellitus (T2DM) und anderen Stoffwechselerkrankungen getestet. Bofanglutide ist ein Prüfpräparat; seine Sicherheit und Wirksamkeit wurden weder von der Europäischen
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 09:17 ET Gan & Lee i Menarini Group łączą siły na rzecz rozwoju bofanglutydu w Europie
klinicznego w schemacie podawania raz na dwa tygodnie w celu kontroli masy ciała u osób dorosłych z otyłością lub nadwagą, a także w leczeniu cukrzycy typu 2 (T2DM) i innych zaburzeń metabolicznych. Bofanglutyd jest badanym związkiem, którego bezpieczeństwo i skuteczność nie zostały dotychczas potwierdzone ani
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 05:37 ET Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe
development under a once-every-two-weeks administration schedule for weight management in adults living with obesity or overweight, type 2 diabetes mellitus (T2DM), and other metabolic conditions. Bofanglutide is an investigational compound; its safety and efficacy have not been established or authorized by the
More news about: Menarini Industrie Farmaceutiche Riunite
Aug 31, 2026, 07:00 ET New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
care-seeking adults in the US in 2024, Truveta (data on file). Comorbidities include atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, obstructive sleep apnea (OSA).3 Enos, Clinton W. et al. Comorbid obesity and history of diabetes are
More news about: Eli Lilly and Company
Aug 28, 2026, 11:41 ET Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)
USAGELISRAYA (brepocitinib) is indicated for the treatment of adults with dermatomyositis (DM).Limitations of UseNot recommended for
More news about: Orsini
Aug 27, 2026, 11:10 ET Builderall Takes on Netlify Drop, Vercel, and Cloudflare Pages With Free AI Website Hosting Built for Small Businesses
subdomain, and a working contact form with email notifications. Upgrading unlocks a custom domain, full email automation, a booking calendar, live chat and DM automation, and Leads Central, a dashboard showing every lead and the channel it came from.Getting a site live requires no complicated account
More news about: Builderall
Aug 27, 2026, 11:00 ET AUKČNÍ DŮM JULIEN'S OZNAMUJE AKCI „KING KAIDŽÚ: SOUBOR VIDEOHER SOMPOTEHO SANDSE"
multimedia:https://www.prnewswire.com/news-releases/aukni-dm-juliens-oznamuje-akci-king-kaidu-soubor-videoher-sompoteho-sandse-302861679.html
More news about: Julien's Auctions
Aug 26, 2026, 23:04 ET Shinsung Materials Strengthens Competitiveness in the Functional Cosmetics Market with Differentiated Ingredient Technologies
response to customer demand for a softer gel texture than OG-DP11, the company is developing a new Dextrin Palmitate product, OG-DP25. Dextrin Myristate (DM14), also under development, is designed to provide appropriate gel strength and a soft texture while maintaining high transparency. Dextrin Palmitate/Ethylhexanoate
More news about: Shinsung Materials Co., Ltd.
Aug 26, 2026, 05:38 ET Global Times: From follower to trendsetter - How China is redefining auto industry
technological path became the first major question facing an industry seeking a breakthrough.In December 2008, BYD launched the F3DM, the world's first mass-produced plug-in hybrid passenger vehicle, ushering China into the era of consumer NEVs. But an early start did not immediately
More news about: Global Times
Aug 18, 2026, 15:00 ET Prosecco DOC Invites Global Culinary Talent to Join 2026 Chef Residency Program
https://drive.google.com/drive/folders/1dm8fprTDaqjisH0ptNhzlq_DxyvDz3Su?usp=drive_linkAbout Prosecco DOC: The Prosecco DOC Consortium (Consorzio di Tutela della Denominazione di
More news about: Prosecco DOC Consortium
Aug 18, 2026, 08:08 ET Sitero Extends Ash, a Clinical AI Agent, Across the Full Clinical Data Lifecycle
approximately 75% faster. The workflow provides continuous data review, query management, and vendor reconciliation through two integrated capabilities. The DM Workbench gives data managers a single, role-based workspace where reviews are auto-assigned based on data type, therapeutic area, and team structure,
More news about: Sitero, LLC
Aug 13, 2026, 11:22 ET In HelloNation, Generator Expert Dan Shaver Highlights Proper Generator Installation
HelloNation article, many homeowners assume that once the equipment is connected and powered on, the work is finished. Dan Shaver of DM Shaver Inc. in Clayton, NY, clarifies that proper generator installation requires much more than basic wiring. It involves planning, precise measurements,
More news about: HelloNation
Aug 13, 2026, 10:01 ET Automotive Software Market worth $83.26 Billion by 2033 | MarketsandMarkets™
Cross to support remote vehicle monitoring and connected services. BYD integrates connected software capabilities into electric models such as the Tang DM i to support vehicle monitoring and digital services. Tesla uses an integrated software platform to support remote diagnostics, over-the-air updates,
More news about: MarketsandMarkets
Aug 11, 2026, 13:45 ET Dreame sẽ ra mắt X60 Ultra Extreme tại Singapore vào ngày 1 tháng 9 năm 2026
bị gia dụng thông minh, nâng cao chất lượng cuộc sống thông qua công nghệ tiên tiến. Nhà phân phối chính thức của Dreame Technology tại Singapore là DM Dasher Pte Ltd. Cập nhật thông tin mới nhất bằng cách theo dõi chúng tôi trên Facebook,
More news about: Dreame Technology
Aug 04, 2026, 08:30 ET Markable Widens Its Lead in Social Commerce With Innovative New Tools That Turn Ideas into Income
@alittlebitofmango"I would never have imagined in a million years that DM automation and all the features that Markable AI offers would truly change my business and make it more profitable than it was. One of my very good content
More news about: Markable AI
Jul 30, 2026, 08:00 ET FeedIRL Launches $10,000 "Sure, Why Not?" Challenge to Plan Your Next Adventure
through Instagram DM. FeedIRL can plan unique date ideas using FeedIRL's Date mode and map out your entire weekend with the Weekend Plan.The "Sure, Why Not?" Challenge turns those recommendations into real-world experiences. To start, follow @feedirl on Instagram and send a DM.Multiple ways
More news about: FeedIRL
Jul 29, 2026, 13:40 ET New Data Show Seed's Co-Biotics Increase Bioactive Vitamin B3, Gut-Brain Metabolites, and Sleep-Related Tryptophan Through the Microbiome
responses across nutrition, energy, and sleep."Presentation Highlights DM-02™ Daily Multivitamin increases bioactive vitamin B3 and lowers colonic pH via the microbiomeDM-02™ is a daily multivitamin formulated for both the body and the microbiome, recognizing the microbiome's
More news about: Seed Health
Jul 28, 2026, 08:00 ET PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent Protecting HemiClor® Formulation Technology
Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, Carter J, Cohen JB, Collins KJ, Commodore-Mensah Y, Davis LL, Egan B, Khan SS, Lloyd-Jones DM, Mazurek Melnyk B, Mistry EA, Ogunniyi MO, Schott SL, Smith SC Jr, Talbot AW, Vongpatanasin W, Watson KE, Whelton PK, Williamson JD. 2025 AHA/ACC/AANP/AAPA/ABC/
More news about: PRM Pharma, LLC
Jul 27, 2026, 09:00 ET KAYALI Celebrates the Launch of Boujee Kitty Caramel Milk with Old Hollywood-Inspired Dallas Experience
$10510ml DM $32
More news about: KAYALI
Jul 23, 2026, 03:00 ET ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
(CNS) activity of its investigational antimiR-23b therapy, ATX-01, in Myotonic Dystrophy Type 1 (DM1). ATX-01 is ARTHEx's investigational RNA therapeutic designed to address the underlying genetic cause of DM1, a highly disabling neuromuscular disorder with no known cure or approved treatment. The
More news about: ARTHEx Biotech